Conditional power calculations for early acceptance of H0 embedded in sequential tests

Area of Science:

• Biostatistics
• Clinical Trial Design
• Sequential Analysis

Background:

• Clinical trials often require early stopping for ethical and efficiency reasons, particularly for strong treatment effects or lack thereof.
• Existing sequential trial designs primarily focus on detecting treatment differences, with less attention to designs for demonstrating no treatment difference.
• Current methods for stopping in favor of the null hypothesis often rely on ad hoc modifications of traditional designs.

Purpose of the Study:

• To extend conditional power calculations for early stopping in favor of the null hypothesis to popular sequential designs.
• To derive explicit monitoring boundaries for sequential tests, aiding in design and power approximations.
• To evaluate these new boundary methods using retrospective analyses of two clinical trials.

Main Methods:

• Extension of conditional power calculations to O'Brien-Fleming and repeated significance tests.
• Derivation of explicit boundaries for monitoring test statistics in sequential trials.
• Retrospective application and comparison of derived boundaries using data from AIDS Clinical Trials Group protocol 118 and Beta-Blocker Heart Attack Trial.

Main Results:

• Explicit boundaries were derived for monitoring sequential tests, facilitating visualization of parameter impacts on operating characteristics.
• The derived boundaries were successfully applied retrospectively to two distinct clinical trial scenarios.
• Numerical examples demonstrated the impact of early stopping in favor of the null hypothesis on trial procedures.

Conclusions:

• The proposed methods provide a framework for designing sequential trials that can stop early for strong evidence of no treatment effect.
• The derived boundaries enhance the design and analysis of sequential trials, offering better control over operating characteristics.
• These advancements contribute to more ethical and efficient clinical trial conduct by allowing early termination when appropriate.